NKX2-1 Antibody

What is NKX2-1 and why is it important in research?

NKX2-1, also known as Thyroid Transcription Factor 1 (TTF1) or Homeobox protein Nkx-2.1, is a transcription factor that plays critical roles in lung development and physiology. It is essential for proper lung development, as NKX2-1-deleted mice exhibit impaired lung development resulting in death at birth due to breathing defects . NKX2-1 is also important in the regulation of genes involved in breathing and innate defense. Additionally, NKX2-1 has significant relevance in cancer research, as it is highly expressed in primary human lung adenocarcinoma and its chromosomal locus (14q13.3) is amplified in approximately 10% of human lung adenocarcinomas . The antibody against NKX2-1 is widely used in clinical settings to distinguish primary lung adenocarcinomas from lung metastases .

What are the recommended applications for NKX2-1 antibodies?

NKX2-1 antibodies are predominantly used in the following research applications:

• Immunohistochemistry (IHC) on formalin/PFA-fixed paraffin-embedded sections at dilutions of 1:500-1000

• Western blot analysis at dilutions of 1:1000-20000

• ChIP-seq assays for determining genome-wide NKX2-1 binding sites in human lung epithelial cells

The optimal working dilution should be determined by the end user based on specific experimental conditions and antibody characteristics . When using NKX2-1 antibodies for Western blotting, TT cell lysates have been validated as appropriate positive controls .

How should NKX2-1 antibodies be stored for optimal performance?

For optimal performance and longevity, NKX2-1 antibodies should be stored at -20°C . It is recommended to aliquot the antibody upon receipt to avoid repeated freezing and thawing cycles, which can diminish antibody activity and performance . The typical storage buffer for NKX2-1 antibodies contains PBS with 50% glycerol, 1% BSA, and 0.09% sodium azide . Researchers should note that sodium azide is a hazardous substance and should be handled by trained personnel only .

What is the specificity profile of NKX2-1 antibodies?

NKX2-1 antibodies primarily react with human TTF1 (Thyroid transcription factor 1), also known as Homeobox protein Nkx-2.1 . Many commercially available antibodies, such as the rabbit recombinant monoclonal antibodies, are raised against a synthetic peptide corresponding to the N-terminus of human NKX2-1 . While these antibodies are validated for human targets, they may also cross-react with mouse and rat TTF1 based on immunogen homology predictions . It is advisable to perform proper validation when using these antibodies in non-human experimental systems.

How can CRISPRi be used to analyze NKX2-1 binding sites and their functional significance?

CRISPRi (CRISPR interference) represents an advanced approach for functional analysis of NKX2-1 binding sites in the genome. This method employs a deactivated Cas9 fused to the KRAB repressor domain (dCas9-KRAB) to repress transcription without creating DNA double-strand breaks . The methodological approach involves:

• Identification of NKX2-1 binding sites through ChIP-seq analysis

• Design of sgRNAs targeting specific DNA elements within or near NKX2-1-binding motifs (CTTG/CAAG)

• Transfection of these sgRNAs into cells stably expressing dCas9-KRAB with or without NKX2-1

• Assessment of target gene expression changes using qPCR or RNA-seq

This approach has successfully identified critical gene-regulatory regions for NKX2-1-dependent expression of genes such as SFTPB, LAMP3, SFTPA1, and SFTPA2 . A key advantage of CRISPRi over traditional CRISPR/Cas9-mediated deletion is that cell cloning is not required, making the workflow more streamlined .

How does NKX2-1 binding relate to chromatin accessibility as determined by ATAC-seq?

Research has revealed a complex relationship between NKX2-1 binding and chromatin accessibility. Interestingly, NKX2-1 appears capable of binding to genomic regions that are considered inaccessible by ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing) . For example, ATAC-seq data from A549 cells obtained from ENCODE indicated that an ATAC peak was not observed at an NKX2-1-binding site in the first intronic region of SFTPB . Similarly, NKX2-1 binding sites in the third and fifth introns of LAMP3 and in the proximal and distal upstream regions of SFTPA1/SFTPA2 were located in ATAC-inaccessible regions .

This suggests that NKX2-1 may function as a pioneer transcription factor capable of accessing compacted chromatin. Researchers should therefore not limit their search for NKX2-1 binding sites to only ATAC-accessible regions when designing experiments to study NKX2-1-mediated gene regulation.

What is the prognostic value of NKX2-1 expression in lung cancer, and how can it be assessed?

NKX2-1 has emerged as a potential biomarker for prognosis in lung squamous cell carcinoma (LUSC). Recent research has demonstrated that:

To assess NKX2-1's prognostic value, researchers can employ:

• Kaplan-Meier survival analysis

• Time-dependent receiver operating characteristic (ROC) curves

• Nomogram construction for predicting LUSC prognosis

• Immunohistochemical staining with validated NKX2-1 antibodies

These approaches can be integrated with additional molecular analyses, such as transcriptomic profiling, to develop comprehensive prognostic models for LUSC patients.

How does NKX2-1 function differently in various cancer contexts?

NKX2-1 exhibits context-dependent functions in cancer biology, acting as either a tumor promoter or tumor suppressor depending on the molecular context. Research has shown that:

• NKX2-1 promotes EGFR-mutant lung tumorigenesis

• NKX2-1 suppresses KRAS-mutant lung tumorigenesis

This dual role complicates the use of NKX2-1 as a therapeutic target or biomarker. Researchers investigating NKX2-1 in cancer should carefully consider the specific genetic background of their experimental models. When using NKX2-1 antibodies for cancer studies, it is essential to characterize the mutational status of key oncogenes like EGFR and KRAS to properly interpret results.

What cell models are appropriate for studying NKX2-1 function?

Selecting appropriate cell models is crucial for NKX2-1 research. Based on the literature, researchers commonly use:

• A549 cells: These cells do not express endogenous NKX2-1 and are therefore useful for gain-of-function studies through exogenous NKX2-1 expression

• H441 cells: These cells naturally express NKX2-1 and are suitable for loss-of-function studies using siRNA or CRISPR approaches

• TT cells: These cells are used as positive controls for Western blot analysis of NKX2-1

When designing experiments, researchers should verify the endogenous NKX2-1 expression status of their chosen cell lines. For gain-of-function studies, the absence of endogenous expression is preferable to avoid confounding effects, while loss-of-function studies require cell lines with robust endogenous expression.

How can researchers validate NKX2-1 antibody specificity in their experimental systems?

Validating antibody specificity is essential for reliable research results. For NKX2-1 antibodies, consider these validation approaches:

• Positive controls: Use cell lines known to express NKX2-1 (e.g., H441 cells) alongside negative controls (e.g., A549 cells without NKX2-1 expression)

• siRNA knockdown: Perform siRNA-mediated knockdown of NKX2-1 in cells with endogenous expression to confirm specificity of antibody signal reduction

• Overexpression systems: Compare cells with and without exogenous NKX2-1 expression

• Multiple antibody comparison: Use different antibody clones targeting distinct epitopes of NKX2-1

• Western blot analysis: Confirm the detection of a single band at the expected molecular weight

Antibody validation should be performed in the specific experimental context (e.g., Western blot, IHC) in which the antibody will be used, as performance can vary across applications.

What genomic approaches can be used to identify and characterize NKX2-1 binding sites?

Researchers have several advanced genomic approaches available for identifying and characterizing NKX2-1 binding sites:

• ChIP-seq: This technique provides an unbiased, genome-wide map of NKX2-1 binding sites in chromatin context

• ATAC-seq: While NKX2-1 can bind to ATAC-inaccessible regions, combining ATAC-seq with ChIP-seq data provides insights into chromatin state at binding sites

• CRISPRi-mediated functional analysis: This approach enables functional assessment of specific NKX2-1 binding sites without altering DNA sequence

• CRISPR/Cas9-mediated deletion: For intergenic binding sites (e.g., the distal upstream region of SFTPA1/SFTPA2), deletion followed by gene expression analysis can confirm functional importance

• RNA-seq following NKX2-1 modulation: This identifies transcriptome-wide effects of NKX2-1 overexpression or knockdown

Integration of these approaches provides comprehensive characterization of NKX2-1 binding sites and their functional significance in gene regulation.

How does NKX2-1 influence the tumor microenvironment and immune cell infiltration?

Recent research has begun to elucidate the relationship between NKX2-1 expression and the tumor microenvironment (TME). Analysis of the correlation between NKX2-1 expression and immune cell infiltration has revealed that NKX2-1 expression is positively associated with several immune cell populations, including:

• Resting mast cells

• Neutrophils

• Monocytes

• Resting CD4 memory T cells

• M2 macrophages

These findings suggest that NKX2-1 may influence tumor progression not only through direct effects on cancer cells but also by modulating the immune microenvironment. Researchers interested in this area should consider combining NKX2-1 antibody-based IHC with multiplex immunofluorescence techniques to simultaneously visualize NKX2-1 expression and immune cell infiltration in tumor tissues.

What pathways and biological processes are enriched in NKX2-1-high versus NKX2-1-low tumors?

Differential gene expression analysis between NKX2-1-high and NKX2-1-low tumors has identified distinct molecular signatures. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) have revealed that differentially expressed genes (DEGs) in NKX2-1-high groups are enriched in:

• Cell cycle pathways

• DNA replication processes

Studies have identified 51 upregulated DEGs and 49 downregulated DEGs in NKX2-1-high groups compared to NKX2-1-low groups . Researchers investigating the molecular mechanisms underlying NKX2-1's role in cancer should consider these pathway enrichments when designing experiments and interpreting results.

How can NKX2-1 expression data be integrated with other biomarkers for improved clinical prognostication?

To enhance the clinical utility of NKX2-1 as a biomarker, researchers can integrate NKX2-1 expression data with other molecular and clinical features. Approaches include:

• Development of nomograms that incorporate NKX2-1 expression with clinical parameters for predicting patient outcomes

• Analysis of the relationship between NKX2-1 expression and tumor mutation burden (TMB)

• Integration of NKX2-1 expression with immune cell infiltration profiles for comprehensive TME characterization

• Correlation of NKX2-1 expression with response to specific therapeutic agents

These integrative approaches have the potential to enhance the prognostic and predictive value of NKX2-1 expression in clinical settings, particularly for lung squamous cell carcinoma patients.

Why might Western blot detection of NKX2-1 show inconsistent results?

Inconsistent Western blot results when detecting NKX2-1 can stem from several technical issues:

• Antibody dilution: NKX2-1 antibodies typically require optimization within a wide range (1:1000-20000) . Insufficient or excessive dilution can lead to weak signals or high background.

• Sample preparation: NKX2-1 is a nuclear protein, and improper nuclear extraction can result in poor detection.

• Storage conditions: Repeated freeze-thaw cycles of antibodies can diminish activity, necessitating proper aliquoting and storage at -20°C .

• Buffer composition: The presence of SDS or other detergents in loading buffers can affect antibody-epitope interactions.

• Transfer efficiency: Improper transfer conditions for nuclear proteins can result in inconsistent band intensity.

To optimize Western blot detection of NKX2-1, researchers should:

• Use positive controls such as TT cell lysates

• Test multiple antibody dilutions to determine optimal concentration

• Ensure complete nuclear extraction through validated protocols

• Optimize transfer conditions specifically for nuclear transcription factors

What controls are essential when designing CRISPRi experiments targeting NKX2-1 binding sites?

When designing CRISPRi experiments to investigate NKX2-1 binding sites, several controls are essential:

• Non-targeting sgRNA control: This control accounts for potential non-specific effects of the CRISPRi system

• Cells with and without NKX2-1 expression: Comparing A549 cells with and without exogenous NKX2-1 expression helps distinguish NKX2-1-dependent effects

• Multiple sgRNAs per target: Using multiple sgRNAs targeting the same binding site can confirm specificity and reduce false negatives

• Off-target validation: RNA-seq analysis following CRISPRi can help identify potential off-target effects

• Positive controls: Including sgRNAs targeting known functional binding sites (e.g., the first intronic region of SFTPB)

Proper experimental design with these controls enhances the reliability of CRISPRi-based functional analysis of NKX2-1 binding sites.